XML 32 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings per Share (Tables)
9 Months Ended
Oct. 29, 2016
Earnings Per Share [Abstract]  
Computation of basic and diluted earnings per share
The following tables show the computation of basic and diluted earnings per common share for each period presented (in thousands, except per share amounts):
 
Three Months Ended
 
Nine Months Ended
 
October 29, 2016
 
October 31, 2015
 
October 29, 2016
 
October 31, 2015
Basic EPS:
 
 
 
 
 
 
 
Net loss
$
(15,634
)
 
$
(10,183
)
 
$
(31,053
)
 
$
(17,205
)
Less: Allocation of earnings to participating securities

 

 

 

Net loss allocated to common shares
(15,634
)
 
(10,183
)
 
(31,053
)
 
(17,205
)
 
 
 
 
 
 
 
 
Basic weighted average shares outstanding
27,155

 
32,017

 
27,066

 
31,917

Basic EPS
$
(0.58
)
 
$
(0.32
)
 
$
(1.15
)
 
$
(0.54
)
 
 
 
 
 
 
 
 
 
Three Months Ended
 
Nine Months Ended
 
October 29, 2016
 
October 31, 2015
 
October 29, 2016
 
October 31, 2015
Diluted EPS:
 
 
 
 
 

 
 

Net loss
$
(15,634
)
 
$
(10,183
)
 
$
(31,053
)
 
$
(17,205
)
Less: Allocation of earnings to participating securities

 

 

 

Net loss allocated to common shares
(15,634
)
 
(10,183
)
 
(31,053
)
 
(17,205
)
 
 
 
 
 
 
 
 
Basic weighted average shares outstanding
27,155

 
32,017

 
27,066

 
31,917

Add: Dilutive effect of stock awards

 

 

 

Diluted weighted average shares outstanding
27,155

 
32,017

 
27,066

 
31,917

Diluted EPS
$
(0.58
)
 
$
(0.32
)
 
$
(1.15
)
 
$
(0.54
)
 
 
 
 
 
 
 
 
Number SARs and non-vested stock excluded from computation of diluted earnings per share
The number of shares attributable to stock options, SARs and non-vested stock grants that would have been considered dilutive securities, but were excluded from the calculation of diluted earnings per common share because the effect was anti-dilutive, were as follows (in thousands):
 
Three Months Ended
 
Nine Months Ended
 
October 29, 2016
 
October 31, 2015
 
October 29, 2016
 
October 31, 2015
Number of anti-dilutive shares due to net loss for the period
20

 
9

 
42

 
52

Number of anti-dilutive SARs due to exercise price greater than average market price of our common stock
187

 
224

 
198

 
158